স্লোভানিয়া - স্লোভেনীয় - JAZMP (Javna agencija RS za zdravila in medicinske pripomočke)

ebewe pharma - azatioprin - filmsko obložena tableta - azatioprin 75 mg / 1 tableta - azatioprin

স্লোভানিয়া - স্লোভেনীয় - JAZMP (Javna agencija RS za zdravila in medicinske pripomočke)

pharmasan d.o.o. - azatioprin - filmsko obložena tableta - azatioprin 50 mg / 1 tableta - azatioprin

ইউরোপীয় ইউনিয়ন - স্লোভেনীয় - EMA (European Medicines Agency)

grünenthal gmbh - lesinurad - hiperurikemija - antigout pripravki - zurampic, v kombinaciji z zaviralec ksantinske oksidaze, je indicirano pri odraslih za dodatno zdravljenje pri bolnikih protina (z ali brez tophi), ki niso dosegli cilj serumu sečne kisline z ustrezno odmerek ksantin-oksidaza hiperurikemija zaviralec sam.

ইউরোপীয় ইউনিয়ন - স্লোভেনীয় - EMA (European Medicines Agency)

gilead sciences ireland uc - emtricitabine, rilpivirine hidroklorid, tenofovir alafenamide - okužbe z virusom hiv - antivirusi za sistemsko uporabo - zdravljenje odraslih in mladostnikov (starih 12 let in starejši z telesne teže vsaj 35 kg), okuženih z virusom človeške imunske pomanjkljivosti (hiv 1) 1 brez znane mutacije, povezane z odpornost proti niso nukleozidni zaviralec reverzne transkriptaze (nnrti) razreda, so ali emtricitabine in z virusna obremenitev ≤ 100.000 hiv 1 rna kopij/ml.

ইউরোপীয় ইউনিয়ন - স্লোভেনীয় - EMA (European Medicines Agency)

gilead sciences ireland uc - emtricitabine, tenofovir alafenamide - okužbe z virusom hiv - antivirusi za sistemsko uporabo - descovy is indicated in combination with other antiretroviral agents for the treatment of adults and adolescents (aged 12 years and older with body weight at least 35 kg) infected with human immunodeficiency virus type 1 (hiv-1).

ইউরোপীয় ইউনিয়ন - স্লোভেনীয় - EMA (European Medicines Agency)

gilead sciences ireland uc - elvitegravir, cobicistat, emtricitabine, tenofovir alafenamide - okužbe z virusom hiv - antivirusi za sistemsko uporabo - genvoya je indicirano za zdravljenje odraslih in mladostnikov (starih 12 let in starejši z telesne teže vsaj 35 kg), okuženih z virusom človeške imunske pomanjkljivosti (hiv 1) 1 brez kakršne koli znane mutacije, povezane z odpornost proti integraze inhibitor razred, emtricitabine ali so.

ইউরোপীয় ইউনিয়ন - স্লোভেনীয় - EMA (European Medicines Agency)

janssen-cilag international nv - darunavir, cobicistat, emtricitabine, tenofovir alafenamide - okužbe z virusom hiv - antivirals for systemic use, antivirals for treatment of hiv infections, combinations - zdravilo symtuza je indicirano za zdravljenje okužbe z virusom humane imunske pomanjkljivosti tipa 1 (hiv-1) pri odraslih in mladostnikih (starih 12 let in več, z telesno maso najmanj 40 kg). genotypic testing should guide the use of symtuza.

ইউরোপীয় ইউনিয়ন - স্লোভেনীয় - EMA (European Medicines Agency)

nova laboratories ireland limited - 6-merkaptopurin monohidrat - leukemija, limfid - antineoplastična sredstva - zdravilo xaluprine je indicirano za zdravljenje akutne limfoblastne levkemije (all) pri odraslih, mladostnikih in otrocih.

ইউরোপীয় ইউনিয়ন - স্লোভেনীয় - EMA (European Medicines Agency)

grunenthal gmbh - allopurinol, lesinurad - protin - antigout pripravki - duzallo je navedeno pri odraslih za zdravljenje hyperuricaemia v protin bolnikih, ki niso dosegli cilja serum ravni sečne kisline z ustrezno dozo allopurinol sam.

ইউরোপীয় ইউনিয়ন - স্লোভেনীয় - EMA (European Medicines Agency)

nova laboratories ireland limited - azathioprine - zavrnitev presadka - imunosupresivi - jayempi is indicated in combination with other immunosuppressive agents for the prophylaxis of transplant rejection in patients receiving allogenic kidney, liver, heart, lung or pancreas transplants. azathioprine is indicated in immunosuppressive regimens as an adjunct to immunosuppressive agents that form the mainstay of treatment (basis immunosuppression). jayempi is used as an immunosuppressant antimetabolite either alone or, more commonly, in combination with other agents (usually corticosteroids) and/ or procedures which influence the immune response. jayempi is indicated in patients who are intolerant to glucocorticosteroids or if the therapeutic response is inadequate despite treatment with high doses of glucocorticosteroids, in the following diseases:severe active rheumatoid arthritis (chronic polyarthritis) that cannot be kept under control by less toxic agents (disease-modifying anti-rheumatic -medicinal products – dmards)auto-immune hepatitis systemic lupus erythematosusdermatomyositispolyarteritis nodosapemphigus vulgaris and bullous pemphigoidbehçet’s diseaserefractory auto-immune haemolytic anaemia, caused by warm igg antibodieschronic refractory idiopathic thrombocytopenic purpurajayempi is used for the treatment of moderately severe to severe forms of chronic inflammatory bowel disease (ibd) (crohn’s disease or ulcerative colitis) in patients in whom glucocorticosteroid therapy is necessary, but where glucocorticosteroids are not tolerated, or in whom the disease is untreatable with other common means of first choice. it is also indicated in adult patients in relapsing multiple sclerosis, if an immunomodulatory therapy is indicated but beta interferon therapy is not possible, or a stable course has been achieved with previous treatment with azathioprine. 3jayempi is indicated for the treatment of generalised myasthenia gravis. depending on the severity of the disease, jayempi should be given in combination with glucocorticosteroids because of slow onset of action at the beginning of treatment and the glucocorticosteroid dose should be gradually reduced after several months of treatment.